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PrognosisAbstract Background: Sentinel lymph node biopsy (SNB) still remains a key procedure to
appropriately stage melanoma patients and to select those who are candidate to novel treat-
ments with immunotherapy and targeted therapy in the adjuvant setting. The impact of timing
of SNB on disease-free survival (DFS) and overall survival (OS) is still unclear.
Material and methods: The study was conducted at 6 Italian Melanoma Intergroup (IMI) cen-
tres and included 8953 consecutive clinical stage I-II melanoma patients who were diagnosed,
treated, and followed up between November 1997 and March 2018. All patients were prospec-
tively included in dedicated IMI database. Multivariable Cox regression analyses were per-
formed to investigate how baseline characteristics and time interval until SNB are related to
DFS and OS.
Results: Considering the whole population, at multivariable analysis, after adjusting for age,
gender, Breslow thickness, site, ulceration, and the SNB status, a delay in the timing of SNB
was associated with a better DFS (adjusted hazard ratio [aHR, delayed versus early SNB] 0.98,
95% confidence interval [CI] 0.97e0.99, p < 0.001) and OS (aHR 0.98, 95% CI 0.97e0.99,
p Z 0.001). Specifically, in patients with a negative SNB status, a beneficial impact of delayed
SNB (i.e. at least 32 days after primary excision) was confirmed for DFS (aHR 0.70, 95%CI
0.63e0.79, p < 0.001) and OS (aHR 0.69, 95%CI 0.61e0.78, p < 0.001), whereas in those with
a positive SNB status, DFS (aHR 0.96, 95%CI 0.84e1.09, p Z 0.534) and OS (aHR 0.94 95%
CI 0.81e1.08, p Z 0.374) were not significantly different in patients with early or delayed
SNB.
Conclusions: Our study does not support a strict time interval for SNB. These results may be
useful for national guidelines, for counselling patients and reducing the number of high ur-
gency referrals.
ª 2020 Elsevier Ltd. All rights reserved.1. Introduction
Primary cutaneous melanoma (PCM) accounts for
only 4% of all skin cancers, but it causes the greatest
number of skin cancer-related deaths worldwide [1].
As for other tumoural histotypes, it is important to
appropriately predict PCM prognosis through reli-
able, validated prognostic biomarkers for patients’
counseling, tailoring appropriate postoperative treat-
ment, and stratification in prospective clinical trials
[2].
The American Joint Committee on Cancer (AJCC)
staging system is the most widely accepted and used
approach to melanoma staging [3]. Patients with early,
locoregional disease are classified into distinct stages
based on Breslow thickness (BT), ulceration, and the
sentinel lymph node (SN) status, which, in turn, in-
cludes the number of positive lymph nodes after
completion lymph node dissection (CLND) in the case
of a positive sentinel node biopsy (SNB).
Recently two clinical trials, the Multicenter Selective
Lymphadenectomy Trial-II and the German Derma-
tologic Cooperative Oncology Group study (DeCOG-
SLT) challenged the need to perform lymphadenec-
tomy, because this procedure does not impact on
outcome and is not informative for staging the vast
majority of patients [4,5].
Nevertheless, SNB still remains a key procedure to
appropriately stage patients and to select those who arecandidate to novel treatments with immunotherapy
and targeted therapy in the adjuvant setting [6]. As a
consequence, it is likely that the number of performed
SNB will increase, and the surgical waiting lists will
lengthen.
Currently, there are conflicting data on the
maximum allowable time interval between PCM
resection and the subsequent wide local excision (WLE)
and SNB. Several experts in the field advocate per-
forming the SNB as soon as possible, but this inevi-
tably negatively affects the routine surgical activity.
The surgeon waiting lists are long particularly for the
small surgical interventions, and this could potentially
affect the way these interventions are performed. In
universal health-care systems covered by the national
healthcare insurance, the urgency to perform as soon as
possible the SNB can potentially push towards pri-
vately executed procedures and introducing disparities.
The Italian Melanoma Intergroup (IMI) core cen-
tres have prospectively collected database with specific
information on diagnosis, histopathological charac-
teristics, timing of surgical procedures, and melanoma-
specific outcome.
The aim of this study was to investigate if time in-
terval between the PCM primary excision (PE) and
SNB is associated with disease-free (DFS) and overall
survival (OS), in the largest cohort of PCM patients so
far reported.
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The approval to conduct the study was obtained from
the local Ethical Committees of the participating cen-
tres. The study included consecutive patients with PCM
diagnosed, treated, and followed-up prospectively in 6
IMI centres (Istituto Nazionale Tumori, Milan, Papa
Giovanni XXIII Cancer Center, Bergamo, Dermato-
logic Clinic of the University of Florence, Veneto
Institute of Oncology of Padua, Department of
Dermatology of the University of Turin and Istituto
Nazionale Tumori, Naples). Since before 1998, SNB was
not routinely performed, and patients with PCM diag-
nosed before 1997 were not considered eligible. The
clinical and pathological parameters extracted from the
database included gender, date of birth, date of diag-
nosis of PCM, date of SNB, BT, ulceration, SN status,
surgical procedures, systemic therapies, and follow-up,
including date of relapse and death.
2.1. Surgical procedures
Diagnosis of the primary melanoma was based on the
excisional biopsy and histopathological examination in
all cases. Excisional biopsy was performed with total
thickness excision and a narrow margin, according to
the Italian guidelines (www.aiom.it).
In all IMI centres, SNB was performed according to
international guidelines criteria. For patients operated
up to 2009, according to AJCC staging 6th edition [7],
SNB was performed in PCM with BT > 1.0 mm or in
presence of risk factors as ulceration, Clark level IV or
V, regression or mitosis >1/mm2. For patients resected
from 2009 up to 2013, SNB was considered, according
to the AJCC staging 7th edition [3], in PCM patients
with BT > 1.0 mm or in presence of risk factors such as
ulceration, Clark level IV or V or mitosis >1/mm2. For
all patients, the WLE, with a margin of 1e2 cm
depending on the BT, and the SNB were performed in
the same setting. SNB was performed according to the
triple technique and histopathological analysis of the SN
was conducted according to the EORTC Melanoma
Group Pathology Protocol [8]. In the event of SNB
positivity, a CLND was performed according to the
international guidelines before the publication of
MSLT2 and DeCOG-SLT trials [4,5].
2.2. Statistical methods
DFS was defined as the time between SNB and disease
relapse or death from any cause. OS was defined as the
time interval between SNB and death from any cause.
Patients who had not relapsed/died or died were
censored at the date of the last follow-up visit. Contin-
uous variables were described using mean and standard
deviation (SD), the median with the first and third
quartile (Q1eQ3; interquartile range, IQR) andminimum and maximum values, whereas categorical
variables were described using frequencies and percent-
ages. Chi-square test (or Fisher’s exact test as appro-
priate) and t-test (or analysis of variance as appropriate)
were performed to compare the distributions of cate-
gorical and continuous variable, respectively. SNB
timing was defined as the time between PE and SNB.
According to the routine activity in IMI centres, patients
who underwent SNB before 1998 or more than 4 months
after the PE were excluded from the analysis. SNB
timing was analysed according three modalities: as
continuous variable accounting for a weekly increase, as
categorical variable defined according to the number of
months from surgery and as dichotomous variable ac-
cording to the best cut-off discriminating the patients
based on DFS, identified by a CART analysis. The ef-
fect of the SNB timing on DFS and OS was explored by
Cox proportional hazard models, stratified by centre,
and adjusted for the demographical and clinical prog-
nostic characteristics. Results of the analysis were
expressed as hazard ratios (HRs), adjusted HRs (aHRs)
and 95% confidence intervals (95%CIs). The propor-
tionality of hazards (PH) was assessed by means of the
Kolmogorov-type supremum test and evaluating the
statistical significance of the interaction of each covari-
ate with time. In case of evidence of no PH for one or
more variables, Cox model including also the interaction
with time of these variables was developed, and HRs at
6 months, 1 and 5 years were provided.
Moreover, a sensitivity analysis according to the
propensity score (PS) approach was performed. The PS
was defined for each patient as the probability to un-
dergo a delayed SNB (after the 32nd day from PE) given
a set of observed characteristics (age, gender, BT, site of
PCM and ulceration), which could have affected the
decision of SNB timing. The estimate of PS was ob-
tained by means of a logistic model having SNB timing
as dependent variable. The Cox models exploring the
SNB timing were adjusted for the PS and for the SN
status.
Survival curves were estimated with the
KaplaneMeier (KM) method and compared using the
log-rank test.
Statistical significance was set at P < 0.05 for a
bilateral test. Analysis was carried out using the SAS
(Statistical Analysis System, SAS Institute, version 9.4)
software and the R (The CRAN Project, Version 3.6.1)
software.3. Results
Between January 1997 and March 2018, 12,112
consecutive patients with PCM were diagnosed in six
IMI centres. Among them, 8953 patients were eligible
for this analysis. eFigure S1 summarises the flow dia-
gram of the study.
Table 1








Age at PE 0.2117
Mean (SD) 54.1 (15.9) 54.6 (15.5) 54.4 (15.6)
Median (Q1eQ3) 54.9 (41.7e66.6) 55.1 (42.7e67.0) 55.0 (42.5e66.9)
Min e Max 0.4e93.0 0.0e93.3 0.0e93.3
Missing 0 1 1
Woman 1234 (45.6) 2925 (46.8) 4159 (46.5) 0.2878
Site <0.0001
Trunk 1179 (43.6) 3035 (48.6) 4214 (47.1)
Lower limb 951 (35.2) 1682 (26.9) 2633 (29.4)
Upper limb 312 (11.5) 795 (12.7) 1107 (12.4)
Head/neck 217 (8.0) 680 (10.9) 897 (10.0)
Other 46 (1.7) 51 (0.8) 97 (1.1)
Missing 1 4 5
Breslow thickness <0.0001
Mean (SD) 2.8 (2.7) 2.4 (2.6) 2.5 (2.6)
Median (Q1eQ3) 2.0 (1.1e3.5) 1.6 (1.0e3.0) 1.7 (1.0e3.2)
Min e Max 0.0e43.0 0.0e65.0 0.0e65.0
Missing 3 3 6
T stage <0.0001
T1 548 (20.3) 1665 (26.7) 2213 (24.7)
T2 867 (32.1) 2138 (34.2) 3005 (33.6)
T3 749 (27.7) 1522 (24.4) 2271 (25.4)
T4 539 (19.9) 919 (14.7) 1458 (16.3)
Missing 3 3 6
Ulceration 994 (39.8) 1822 (30.7) 2816 (33.4) <0.0001
Missing 206 321 527
SNB timing e
Mean (SD) 15.6 (11.7) 62.1 (20.6) 48.1 (28.2)
Median (Q1eQ3) 19.0 (0.0e27.0) 60.0 (45.0e76.0) 47.0 (28.0e68.0)
Min e Max 0.0e31.0 32.0e121.0 0.0e121.0
SNB timing e monthly categorisation e
One month from PE 2557 (94.5) 0 (0.0) 2557 (28.6)
Two months from PE 149 (5.5) 3206 (51.3) 3355 (37.5)
Three/four months from PE 0 (0.0) 3041 (48.7) 3041 (34.0)
SN status <0.0001*
Negative 1875 (69.3) 4732 (75.7) 6607 (73.8)
Positive 826 (30.5) 1503 (24.1) 2329 (26.0)
Not found 4 (0.1) 12 (0.2) 16 (0.2)
Missing 1 0 1
CLND in positive SN patients 0.0245
Yes 790 (97.8) 1414 (96.0) 2204
No 18 (2.2) 59 (4.0) 77
Missing 18 30 48
Early SNB, sentinel node biopsy performed within 31 days of primary excision; Delayed SNB, sentinel node biopsy performed at least 31 days after
the primary excision; SNB, sentinel node biopsy; SN, sentinel node; PE, primary excision; CLND, complete lymph node dissection; SD, standard
deviation; Q1eQ3, first quartileethird quartile.
* Comparison performed excluding patients with sentinel node not found.
M. Mandalà et al. / European Journal of Cancer 137 (2020) 30e39 33A comparison among centres in terms of de-
mographic and clinical characteristics at diagnosis is
reported in eTable 1. The mean timing of SNB ranged
from 22.6 days (SD 16.8) to 53.4 days (SD 29.1). Table 1
shows the demographic and clinical characteristics ac-
cording to the best cut-off of SNB timing identified by
the CART analysis (i.e. 31 days). Overall, 2706 (30.2%)
and 6247 (69.8%) patients underwent SNB within (early
SNB) or after (delayed SNB) 31 days from the PE,
respectively. The mean SNB timing was 15.6 days (SD11.7) in the early SNB group and 62.1 days (SD 20.6) in
the delayed SNB group. The proportion of patients with
a positive SN was significantly higher in the early SNB
group (30.5% and 24.1% for early and delayed SNB
respectively, p < 0.0001).
The median follow-up was 95.9 months (IQR
52.4e132.1). In the early SNB group, 788 (29.1%) pa-
tients relapsed, 854 (31.6%) died and 1045 (38.6%)
relapsed or died without relapse (i.e. DFS events). In the
delayed SNB group, 1096 (17.5%) patients relapsed,
Table 2
Effect of the SNB timing on relapse free survival. Univariate and multivariable Cox proportional hazard model stratified by centre.
Variable Univariate models Multivariable model 1 Multivariable model 2 Multivariable model 3
HR [95%CI] p-value HR [95%CI] p-value HR [95%CI] p-value HR [95%CI] p-value
SNB timing
(1 week increase)
0.95 [0.94e0.96] <0.0001 0.98 [0.97e0.99] <0.0001 e e e e
SNB timing*
(ref.
Month 1 after PE)
Month 2 after PE 0.74 [0.68e0.81] <0.0001 e e 0.83 [0.75e0.91] 0.0001 e e
Month 3e4 after PE 0.68 [0.61e0.75] <0.0001 e e 0.82 [0.74e0.92] 0.0004 e e
SNB timing >31 days 0.70 [0.64e0.76] <0.0001 e e e e 0.81 [0.74e0.88] <0.0001
Breslow thickness
(1 mm increase)
1.08 [1.08e1.09] <0.0001 1.06 [1.05e1.07] <0.0001 1.06 [1.05e1.07] <0.0001 1.06 [1.05e1.07] <0.0001
Age at surgery*
(1 year increase)
1.03 [1.03e1.03] <0.0001 1.03 [1.02e1.03] <0.0001 1.03 [1.02e1.03] <0.0001 1.03 [1.02e1.03] <0.0001
Female sex 0.72 [0.66e0.78] <0.0001 0.84 [0.77e0.91] <0.0001 0.84 [0.77e0.91] <0.0001 0.84 [0.77e0.91] <0.0001
Site* (ref. Trunk)
Lower limb 1.02 [0.93e1.12] 0.6131 0.98 [0.89e1.08] 0.6684 0.98 [0.89e1.09] 0.7338 0.98 [0.89e1.08] 0.6871
Upper limb 0.89 [0.78e1.02] 0.0833 0.86 [0.75e0.99] 0.0389 0.87 [0.76e1.00] 0.0468 0.87 [0.76e1.00] 0.0463
Head/neck 1.63 [1.44e1.84] <0.0001 1.60 [1.41e1.81] <0.0001 1.60 [1.41e1.82] <0.0001 1.61 [1.41e1.82] <0.0001
Other 3.41 [2.56e4.55] <0.0001 1.88 [1.40e2.54] <0.0001 1.88 [1.40e2.54] <0.0001 1.87 [1.39e2.53] <0.0001
Ulceration* 2.97 [2.73e3.22] <0.0001 2.05 [1.88e2.23] <0.0001 2.06 [1.90e2.25] <0.0001 2.06 [1.89e2.24] <0.0001
SNB outcome*
(ref. Absent)
Positive 2.57 [2.37e2.78] <0.0001 2.14 [1.96e2.33] <0.0001 2.15 [1.97e2.34] <0.0001 2.14 [1.96e2.34] <0.0001
Not found 1.83 [0.82e4.08] 0.1403 1.17 [0.44e3.13] 0.7532 1.18 [0.44e3.16] 0.7390 1.19 [0.44e3.17] 0.7349
SNB, sentinel node biopsy; PE, primary excision; CI, confidence interval; HR, hazards ratio.
Effect of 1 week increase of SNB timing adjusted for also the interactions with time of the variables with * is HR [1 week increase] 0.98 [95%CI
0.97e0.99], p Z 0.0001.
Effect of SNB timing >31 days adjusted for also the interactions with time of the variables with * is HR 0.81 [95%CI 0.75e0.89], p < 0.0001.
* Evidences of non-proportionality of hazards.
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without relapse. Tables 2 and 3 report the univariable
and multivariable analyses on DFS and OS, respec-
tively. For both end-points, evidence of no PH was
found for age, site of PCM, ulceration and SN status.
Moreover, no PH was detected for BT in the analysis on
DFS and for SNB timing with monthly categorisation in
the analysis on OS. At multivariable analysis, after
adjusting for age, gender, BT, site, ulceration and the
SN status, a delay in the timing of SNB was associated
with a better DFS (aHR [1 week increase] 0.98, 95%
confidence interval [CI] 0.97e0.99, p < 0.0001) and OS
(aHR [1 week increase] 0.98, 95%CI 0.97e0.99,
p Z 0.0006). Similar results were observed after
adjusting for the interaction with time of variables with
no PH.
A positive impact on DFS was found in patients who
underwent SNB at the second or third/fourth month
after the PE (aHR [second versus first month] 0.83 95%
CI 0.75e0.91, pZ 0.0001; aHR [third/fourth versus first
month] 0.82 95%CI 0.74e0.92, p Z 0.0004). Most
importantly, a longer OS was observed in patients who
underwent SNB at the second and third/fourth month
after the PE (aHR [second versus first month] 0.76 95%
CI 0.69e0.85, p < 0.0001; aHR [third/fourth versus first
month] 0.85 95%CI 0.75e0.95, p Z 0.0062). Similarresults on OS were observed after adjusting for the
interaction with time of variables with no PH. Fig. 1A
and B shows the KM curves according to the SNB
timing for DFS and OS, respectively.
Considering the cut-off defined according to the
CART analysis, a SNB performed at least 32 days after
the PE was associated with both a better DSF (aHR
0.81, 95%CI 0.74e0.88, p < 0.0001) and OS (aHR 0.78,
95%CI 0.71e0.85, p < 0.0001). Similar results were
observed after adjusting for the interaction with time of
variables with no PH or adjusting for the propensity
score (DFS: aHR [delayed versus early SNB] 0.81, 95%
CI 0.75e0.88, p < 0.0001; OS: aHR [delayed versus
early SNB] 0.80, 95%CI 0.73e0.88, p < 0.0001). Fig. 1C
and D show the KM curves for DFS and OS according
to the cut-off determined by CART analysis.
eTables 2 and 3 report the HRs at 6 months, 1 and 5
years of variables with evidence of no PH. Although
evidence of no PH, the variations of the HRs at 6
months, 1 and 5 years seem to be negligible.
Given the above results, we performed a subgroup
analysis in patients with negative and positive SN,
respectively. Fig. 2 summarises the multivariable Cox
analysis according to this subgroup analysis.
In patients with a negative SN status, a beneficial
impact of delayed SNB (i.e. at least 32 days after PE)
Table 3
Effect of the time to SNB on overall survival. Univariate and multivariable Cox proportional hazard model stratified by centre.
Variable Univariate models Multivariable model 1 Multivariable model 2 Multivariable model 3
HR [95%CI] p-value HR [95%CI] p-value HR [95%CI] p-value HR [95%CI] p-value
SNB timing
(1 week increase)
0.96 [0.95e0.97] <0.0001 0.98 [0.97e0.99] 0.0006 e e e e
SNB timing*
(ref.
Month 1 after PE)
Month 2 after PE 0.73 [0.66e0.81] <0.0001 e e 0.76 [0.69e0.85] <0.0001 e e
Month 3e4 after PE 0.74 [0.66e0.83] <0.0001 e e 0.85 [0.75e0.95] 0.0062 e e
SNB timing >31 days 0.72 [0.65e0.78] <0.0001 e e e e 0.78 [0.71e0.85] <0.0001
Breslow thickness*
(1 mm increase)
1.09 [1.09e1.10] <0.0001 1.07 [1.06e1.08] <0.0001 1.07 [1.06e1.08] <0.0001 1.07 [1.06e1.08] <0.0001
Age at surgery*
(1 year increase)
1.04 [1.04e1.04] <0.0001 1.04 [1.03e1.04] <0.0001 1.04 [1.03e1.04] <0.0001 1.04 [1.03e1.04] <0.0001
Female sex 0.63 [0.58e0.69] <0.0001 0.77 [0.70e0.85] <0.0001 0.78 [0.70e0.86] <0.0001 0.78 [0.71e0.86] <0.0001
Site* (ref. Trunk)
Lower limb 0.88 [0.80e0.98] 0.0202 0.85 [0.75e0.95] 0.0038 0.85 [0.76e0.95] 0.0037 0.84 [0.75e0.94] 0.0025
Upper limb 0.88 [0.76e1.02] 0.1004 0.84 [0.72e0.98] 0.0290 0.85 [0.73e0.99] 0.0373 0.85 [0.72e0.99] 0.0322
Head/neck 1.45 [1.27e1.67] <0.0001 1.36 [1.18e1.57] <0.0001 1.36 [1.18e1.58] <0.0001 1.37 [1.18e1.58] <0.0001
Other 3.31 [2.43e4.51] <0.0001 1.83 [1.33e2.52] 0.0002 1.83 [1.33e2.52] 0.0002 1.81 [1.32e2.50] 0.0003
Ulceration* 3.12 [2.85e3.42] <0.0001 2.16 [1.96e2.38] <0.0001 2.18 [1.98e2.40] <0.0001 2.17 [1.97e2.38] <0.0001
SNB outcome*
(ref. Absent)
Positive 2.51 [2.30e2.75] <0.0001 2.03 [1.84e2.24] <0.0001 2.07 [1.87e2.28] <0.0001 2.03 [1.84e2.24] <0.0001
Not found 1.61 [0.60e4.30] 0.3432 0.67 [0.17e2.69] 0.5731 0.67 [0.17e2.67] 0.5655 0.66 [0.16e2.66] 0.5604
SNB, sentinel node biopsy; PE, primary excision; CI, confidence interval; HR, hazards ratio.
Effect of 1 week increase of SNB timing adjusted for also the interactions with time of the variables with * is HR [1 week increase] 0.98 [95%CI
0.97e0.99], p Z 0.0016.
Effect of doing the SLNB during the second month from PE adjusted for also the interactions with time of the variables with * is HR 0.77 [95%CI
0.69e0.86], p < 0.0001.
Effect of doing the SLNB during the third/fourth month from PE adjusted for also the interactions with time of the variables with * is HR 0.86
[95%CI 0.76e0.97], p Z 0.0125.
Effect of SNB timing >31 days adjusted for also the interactions with time of the variables with * is HR 0.79 [95%CI 0.72e0.86], p < 0.0001.
* Evidences of non-proportionality of hazards.
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p < 0.0001) and OS (aHR 0.69 95%CI 0.61e0.78,
p < 0.0001). In patients with a positive SN status, DFS
(aHR [delayed versus early SNB] 0.96 95%CI 0.84e1.09,
p Z 0.5339) and OS (aHR [delayed versus early SNB]
0.94 95%CI 0.81e1.08, p Z 0.3738) were not signifi-
cantly different between patients with early or delayed
SNB.
4. Discussion
The most striking result of our study is that the in-
terval between excision of a PCM and the SNB could
have a prognostic impact in patients with a negative SN,
being DFS and OS worse in patients who undergo early
SNB, whereas no effect was found in patients with
positive SN. In patients with negative SN, the delayed
SNB procedure was associated with a 30% risk reduc-
tion of recurrence and/or death.
The results of our study could have some important
clinical implications. From a clinical standpoint, ourresults do not support a strict time interval for WLE and
SNB, and this notion could be important for national
guidelines and to counsel patients and reduce the num-
ber of high urgency referrals.
In our series, a higher proportion of positive SN was
found in early versus delayed SNB subgroup of pa-
tients (30.5% versus 24.1%). Moreover, patients who
underwent an early SNB had a higher median BT
(2.0 mm versus 1.6 mm) and more ulcerated mela-
nomas (39.8% versus 30.7%). A positive SN was
associated to well-known unfavourable prognostic
factors, and we cannot exclude that physicians may
have selected patients to get an early SNB owing to
negative prognostic factors.
The results of the present study should be considered
in the context of the current literature. To date, the
impact of a longer time interval until SNB on DFS and
OS has been reported in 11 studies [9e19], which
included patients with negative and/or positive SN
(Table 4). The results so far reported are conflicting
because of heterogeneity in patients’ characteristics,
Fig. 1. Kaplan-Meier curves showing disease-free survival and overall survival according to SNB timing categorised monthly (A and B)
and according to CART analysis (C and D). SNB, sentinel node biopsy; PE, primary excision.
M. Mandalà et al. / European Journal of Cancer 137 (2020) 30e3936number of patients included according to the SN status,
the time interval to SNB which varies from 7 to 59 days
and finally, the median follow-up.
With regards to SN-positive patients, while Fortes
et al. found a benefit of early SNB [9], three other large
studies did not [12,13,18]. Specifically, Tejera-Vaquerizo
[13] reported that interval to SNB had no effects on
survival in a SN-positive cohort of 464 patients. Simi-
larly, in two large, well-conducted studies by the
EORTC melanoma group, including 1015 and 705 pa-
tients, respectively, the interval between primary mela-
noma excision and SNB was not associated with
survival in SN-positive patients. Our study confirms
these findings [12,18].
With regards to SN-negative cohorts, the results are
still conflicting. In seven studies, the interval between
primary melanoma excision and SNB was not associated
with DFS and/or OS [9e12,14,17,19]. More recently,
Tejera-Vaquerizo et al. [13], in a retrospective study
including 1498 SN-negative patients, did find adetrimental effect of a short time interval on OS. Our
study included 6607 SN-negative patients, and again a
strong effect of time interval was found in this relatively
low risk melanoma population.
Melanoma is an immunogenic cancer. Melanoma
cells display multiple antigens and peptide epitopes that
are targetable by the host immune system, and several
immunotherapy strategies have been developed in the
adjuvant and metastatic setting in the last decade.
Induction of a specific, clonal antitumour T-cell
response depends on the priming of specific naıve T cells
by antigen presenting cells in the draining lymph nodes
[20]. When a specific antigen is presented by antigen
presenting cells, the naıve T cells are activated [21].
Priming of helper and cytotoxic antitumour T cells
seems to take place in the SN and potentially is associ-
ated with an antitumour T-cell response in melanoma.
Nevertheless, several steps are required for an effi-
cient immune response including the transport, pro-
cessing and presentation of melanoma antigens in the
Fig. 2. Subgroup analysis on disease-free survival and overall sur-
vival according to SN status. SN, sentinel lymph node; SNB,
sentinel node biopsy; PE, primary excision; CI, confidence inter-
val; HR, hazards ratio.
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subsequent priming of tumour antigenespecific T cells.
The SN is the first lymphoid organ that tumour antigens
meet after being released from a primary tumour intothe lymphatic drainage. SNs are thought to be more
closely associated with antitumour immunity than non-
SNs [22]. However, the presence of melanoma inhibits
an immune response by releasing immunosuppressive
cytokines and creating an immunosuppressive micro-
environment [23,24]. After excision of primary mela-
noma, processing, maturation of antigen presenting
cells, antigen presentation and priming require time.
Indeed, an immune response requires precise coordina-
tion of molecular and cellular signaling, tightly regu-
lated with multistep cascades, which occur over multiple
time and length scales [25]. Our results suggest that early
excision of negative SN may, after removal of primary
melanoma, impair and stop this process and is therefore
associated with a worse DFS and OS. Nevertheless, the
interval between melanoma development and the diag-
nostic biopsy is likely to be greater and more variable
than the interval between biopsy and SNB. This inter-
val, which is more difficult to measure, should be
considered as well, and this represent an area of future
translational and preclinical investigations.
This study adds novel information to the current
literature for several reasons: 1) it is the largest analysis
to date on the effect of timing of SNB on survival; 2) all
included patients were treated in the context of IMI
centres with homogeneous surgical procedures and
similar schedule of follow-up; 3) a robust statistical
analysis allowed us to evaluate the impact of timing to
SNB through different models: i) timing to SNB as a
continuous variable, ii) timing to SNB in discrete cate-
gories (months after primary resection), iii) and two
different groups according to the CART analysis.
Importantly, these results were confirmed by a sensi-
tivity analysis according to the PS approach; 4) we
provided a comprehensive overview of all studies to date
published; 5) the median follow-up is one of the longest
so far reported; and 6) our data suggest that a time in-
terval until 4 months may be not detrimental for pa-
tients with both positive and negative SN.
We are also aware of some limitations, including 1)
the retrospective nature of our analysis, which cannot
exclude patient enrollment bias, 2) the histopathological
review was not centralised among participating centres,
which can increase heterogeneity in the characterization
of tumour variables, 3) the lack of a validation cohort.
Our study, in the context of the current literature, has
clinical implications considering that the number of
performed SNBs will increase, as it is now a gateway to
effective adjuvant therapy in stage III. Furthermore, the
current COVID-19 pandemic may raise issues in the
time schedule of surgical procedures.
In conclusion, our data do not support a strict time
interval for SNB, and considering our results and those
of previous studies, this notion should be incorporated
in current guidelines and to counsel patients to reduce
the number of high urgency referrals.
Table 4














Fortes [9] SN: 607
SNþ:141
30 Not specified Not reported SN: HR [Early versus
delayed]
1.77, 95%CI 0.97e3.26




Carpenter [10] SN: 412
SNþ: 61
28 (A) and 56 (B) 2.8 years A) HR [Early versus
delayed]
1.01, 95%CI 0.64e1.58
B) HR [Early versus
delayed]
0.80, 95%CI 0.37e1.73
A) HR [Early versus
delayed] 1.05, 95%CI 0.61
e1.82
B) HR [Early versus
delayed] 0.89, 95%CI 0.34
e2.34




3.34 years Not reported HR [1 day increase] 0.89,
95%CI 0.74e1.07
[OS calculated from the
primary melanoma
excision]
Oude Ophuis [12] SN: 2841
SNþ: 705
43 50 months Not reported HR [1 day increase] 1.0,
95%CI 0.99e1.01
Tejera-Vaquerizo [13] SN: 1498
SNþ: 464
40 46 months Not significant for SN
 and SNþ (data not
shown) [DFS calculated
from the excision of the
primary melanoma
plus 120 days]
SN: HR [Early versus
delayed] 2.6, 95%CI 1.5
e4.6
SNþ: Not significant (data
not shown)
[OS calculated from the
excision
of the primary melanoma
plus
120 days. MSS]
Nelson [14] SN: 2051
SNþ: 432
30 95.7 months HR [Early versus delayed]
0.98, 95%CI 0.81e1.18)
HR [Early versus delayed]
1.05, 95%CI 0.83e1.34
[MSS ]
Tejera-Vaquerizo [15] SN: 274
SNþ: 66
SN not found: 10










Richtig [16] SNþ: 121 43 42 months Not reported Not reported
Gambichler [17] SN: 667
SNþ: 229
7 Not specified Not reported] Not reported
Oude Ophuis [18] SNþ:1015 47 36 months Not reported HR [1 day increase] 1.0,
95%CI 0.99e1.01
Parrett [19] SN: 414
SNþ: 78
40 11.7 years HR [Delayed versus early]
0.91,
95%CI 0.64e1.28
HR [Delayed versus early]
0.91, 95%CI 0.67e1.23
[MSS ]
MSS, melanoma-specific survival; SN, sentinel lymph node; SN, negative sentinel lymph node; SNþ, positive sentinel lymph node; SNB, sentinel
lymph node biopsy; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; 95%CI, 95% confidence interval.
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[17] Gambichler T, Bünnemann H, Scheel CH, et al. Does early timing
of lymph node surgery after resection of the primary tumour
improve the clinical outcome of melanoma patients? Clin Exp
Derm Epub 2020. https://doi.org/10.1111/ced.14291.
[18] Oude Ophuis CM, Verhoef C, Rutkowski P, et al. The interval
between primary melanoma excision and sentinel node biopsy is
not associated with survival in sentinel node positive patientsdAn
EORTC Melanoma Group study. Eur J Surg Oncol 2016;42:
1906e13.
[19] Parrett BM, Accortt NA, Li R, et al. The effect of delay time
between primary melanoma biopsy and sentinel lymph node
dissection on sentinel node status, recurrence, and survival. Mel-
anoma Res 2012;22:386e91.
[20] Heath WR, Carbone FR. Cross-presentation, dendritic cells,
tolerance and immunity. Annu Rev Immunol 2001;19:47e64.
[21] Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune
contexture in human tumours: impact on clinical outcome. Nat
Rev Canc 2012;12:298e306.
[22] Sakakura K, Chikamatsu K, Sakurai T, et al. Infiltration of
dendritic cells and NK cells into the sentinel lymph node in oral
cavity cancer. Oral Oncol 2005;41:89e96.
[23] Leong SP, Peng M, Zhou YM, et al. Cytokine profiles of sentinel
lymph nodes draining the primary melanoma. Ann Surg Oncol
2002;9:82e7.
[24] Lee JH, Torisu-Itakara H, Cochran AJ, et al. Quantitative
analysis of melanoma-induced cytokine-mediated immuno-
suppression in melanoma sentinel nodes. Clin Canc Res 2005;
11:107e12.
[25] Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immu-
noediting. Annu Rev Immunol 2004;22:329e60.
